Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC
Barend Sikkema, PHD Candidate at Erasmus MC, shared a recent article on LinkedIn:
“Publication Alert.
Our latest article titled Body weight gain associated with alectinib in patients with ALK positive non-small cell lung cancer: pooled analysis of individual patient data from 4 prospective clinical trials, is now available online in the Journal of Clinical Oncology.
Aim: To analyze body weight changes over time and investigate whether baseline patient characteristics are linked to changes in weight.
Key findings:
- 49% of patients experienced ≥ 5% body weight gain, and 18% gained ≥ 10% during alectinib treatment. Off note, weight gain is not reported in similar effective SMKI’s such as osimertinib in EGFR positive NSCLC.
- Notably, follow-up body weights were not systematically recorded in the landmark ALEX trial.
- No readily available clinical baseline characteristic was clinically meaningful associated with weight gain, making it challenging to identify patients at risk before start of treatment.
Our study reveals the underreporting of body weight gain in clinical trials and our findings emphasize the need for greater awareness among clinicians of this overlooked adverse event.
Takeaway for clinicians: Monitor body weight changes and preferably also waist circumference – closely in patients on alectinib.”
Authors: Barend J. Sikkema, Sara J. Baart, Marthe S. Paats, Egbert F. Smit, Annemie MWJ Schols, Ron HJ Mathijssen, Elisabeth FC van Rossum and Anne-Marie C. Dingemans
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023